Randox biochip detects up to 97 drug metabolites simultaneously
4 April 2011
Northern Irish company Randox Laboratories has developed
Biochip Array Technology that allows clinicians to detect up to 97 drug
metabolites from one sample simultaneously.
The technology has already been used in drug screening programmes
around the globe, including the UK, Italy and Vietnam.
The ability to carry out simultaneous tests on a biochip has lead
to significant time and labour savings in WDT, whereas traditionally
only one drug could be detected at a time.
The Randox Biochip portfolio incorporates a range of illicit and
prescription drugs which can be mis-used, putting employees at risk
while they are at work. High-risk industries which commonly employ
WDT include construction, manufacturing, transport, education and
Last year, The National Institute on Drug Abuse (NIDA) published
a report indicating that drug abuse worldwide was at its highest
level in nearly a decade. Findings revealed that the most commonly
abused drug is Marijuana; however non-medical use of prescription
drugs is also increasing.
In 2010, Randox Global Toxicology Manager Richard Bell revealed
that the company had experienced significant growth in the demand
for their range of workplace drug testing products: “Workplace drug
testing is becoming a necessity prior to employment, both for the
safety of employees and members of the public who they may come in
contact with. We cannot ignore the fact that drug mis-use is on the
rise. Randox are continuously developing our drug screening test
menu to accommodate companies carrying out a workplace drug testing